BioMerieux Operating Income 2017-2024 | BMXMF

BioMerieux operating income for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • BioMerieux annual operating income for 2024 was $0.637B, a 34.07% increase from 2023.
  • BioMerieux annual operating income for 2023 was $0.475B, a 23.18% decline from 2022.
  • BioMerieux annual operating income for 2022 was $0.619B, a 33.31% decline from 2021.

BioMerieux Operating Income 2017-2024 | BMXMF

  • BioMerieux annual operating income for 2024 was $0.637B, a 34.07% increase from 2023.
  • BioMerieux annual operating income for 2023 was $0.475B, a 23.18% decline from 2022.
  • BioMerieux annual operating income for 2022 was $0.619B, a 33.31% decline from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$138B
CVS Health (CVS)$80.9B
Elevance Health (ELV)$76B
Cencora (COR)$57.1B
DiDi Global (DIDIY)$25.8B
Labcorp Holdings (LH)$20.6B
Natera (NTRA)$20.5B
EUROFINS SCIENT (ERFSF)$13.6B
CochLear (CHEOY)$12.8B
Solventum (SOLV)$12.7B
ICON (ICLR)$11.8B
Revvity (RVTY)$11.3B
Viatris (VTRS)$10.5B
Medpace Holdings (MEDP)$9B
Sonic Healthcare (SKHHY)$8.8B
Avantor (AVTR)$8.7B
HealthEquity (HQY)$8.3B
Charles River Laboratories (CRL)$7.6B
Caris Life Sciences,�Inc (CAI)$7.4B
Amplifon S.p.A (AMFPF)$5.4B
Bausch + Lomb (BLCO)$4.9B
BrightSpring Health Services (BTSG)$3.5B
Sotera Health (SHC)$3.2B
Surgery Partners (SGRY)$2.8B
Alignment Healthcare (ALHC)$2.6B
Concentras Parent (CON)$2.5B
Organon (OGN)$2.5B
GeneDx Holdings (WGS)$2.3B
Progyny (PGNY)$2B
Ardent Health (ARDT)$2B